The FDA has accepted the NDA for ADS-5102 for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease.
Lea Eslava-Kim, PharmDDrug Information Specialist https://www.neurologyadvisor.com
Lea Eslava-Kim, PharmD, is a Drug Information Specialist for MPR. She received her doctorate in pharmacy from the Ernest Mario School of Pharmacy, Rutgers University and completed her pharmacy residency at Clara Maass Medical Center. She is a licensed pharmacist.